WO2007119576A9 - Procede de production d'un acide l-amine en utilisant une bacterie de la famille des enterobacteries - Google Patents

Procede de production d'un acide l-amine en utilisant une bacterie de la famille des enterobacteries

Info

Publication number
WO2007119576A9
WO2007119576A9 PCT/JP2007/056757 JP2007056757W WO2007119576A9 WO 2007119576 A9 WO2007119576 A9 WO 2007119576A9 JP 2007056757 W JP2007056757 W JP 2007056757W WO 2007119576 A9 WO2007119576 A9 WO 2007119576A9
Authority
WO
WIPO (PCT)
Prior art keywords
gene
amino acid
bacterium
mutant
glucose
Prior art date
Application number
PCT/JP2007/056757
Other languages
English (en)
Other versions
WO2007119576A1 (fr
Inventor
Veronika Aleksandro Kotliarova
Irina Borisovna Altman
Leonid Romanovich Ptitsyn
Yury Ivanovich Kozlov
Original Assignee
Ajinomoto Kk
Veronika Aleksandro Kotliarova
Irina Borisovna Altman
Leonid Romanovich Ptitsyn
Yury Ivanovich Kozlov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2006109061/13A external-priority patent/RU2335536C2/ru
Application filed by Ajinomoto Kk, Veronika Aleksandro Kotliarova, Irina Borisovna Altman, Leonid Romanovich Ptitsyn, Yury Ivanovich Kozlov filed Critical Ajinomoto Kk
Publication of WO2007119576A1 publication Critical patent/WO2007119576A1/fr
Publication of WO2007119576A9 publication Critical patent/WO2007119576A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine

Definitions

  • the present invention relates to a method for producing an L-amino acid by fermentation, and more specifically to genes which aid in this fermentation. These genes are useful for improving L-amino acid production, particularly L-threonine.
  • L-amino acids are industrially produced by fermentation methods utilizing strains of microorganisms obtained from natural sources, or mutants thereof. Typically, the microorganisms are modified to enhance production yields of L-amino acids.
  • Phosphoenolpyruvate carbohydrate phosphotransferase systems, p. 1149-1174.
  • F. C. Neidhardt, R. Curtiss III J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed. American Society for Microbiology, Washington, D.C.)
  • D-glucose In Escherichia coli K- 12, D-glucose (GIc) is taken up and concomitantly phosphorylated either by the glucose-specific enzyme II (EII) transporter (II Glc ) (glucose- specific PTS permease) or the mannose-specific EII transporter (II Man ) (manXYZ genes) of PTS.
  • EII glucose-specific enzyme II
  • II Man mannose-specific EII transporter
  • the phosphoryl groups are sequentially transferred from PEP through two common intermediates, enzyme I (EI; gene: ptsT) and the phosphohistidine carrier protein (HPr; gene: ptsH), to sugar-specific protein EII (IICB G1 °) and then to glucose.
  • II Glc consists of two subunits, IIA Glc (encoded by err gene (catabolite repression resistance)) and membrane-bound IICB Glc (encoded hyptsG gene).
  • the err gene is part of the ptsHI err operon, and is separated from the ptsG gene, which maps at 25.0 min.
  • the IICB Glc subunit is composed of an amino-terminal, hydrophobic IIC Glc domain, which largely determines substrate specificity, and a carboxy-terminal, hydrophilic IIB Glc domain, which is phosphorylated at the Cys421 residue.
  • the EIICB GlQ has a limited range of substrates; it is the major transporter for GIc but it is also capable of transporting mannose and the non-metabolizable GIc analogue a- methylglucoside. However, EIICB Glc is normally incapable of transporting the amino sugars.
  • the expression of ptsG is controlled by the mlc-encoded transcription factor. Growth on GIc induces ptsG expression presumably by relieving MIc repression (Plumbridge, J., Microbiology, 146, 2655-2663 (2000); Seitz, S. et al, J. Biol. Chem., 278, 12, pp. 10744-10751 (2003)).
  • Objects of the present invention include enhancing the productivity of L-amino acid-producing strains and providing a method for producing L-amino acids using these strains.
  • (B) a variant of protein (A), which has glucose-specific PTS permease activity when combined with the HA (Crr) subunit.
  • L-amino acid is selected from the group consisting of an aromatic L- amino acid and a non-aromatic L-amino acid.
  • non-aromatic L-amino acid is selected from the group consisting of L- threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L- valine, L- histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartate, L-glutamine, L-glutamic acid, L-proline, and L-arginine.
  • L-amino acid is selected from the group consisting of an aromatic L-amino acid and a non-aromatic L-amino acid.
  • aromatic L-amino acid is selected from the group consisting of L- phenylalanine, L-tyrosine, and L-tryptophan.
  • L-amino acid is selected from the group consisting of L-threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L-histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, and L- arginine.
  • Figure 1 shows the alignment of the primary sequences of IIB/IIC subunit of glucose-specific PTS permease from Escherichia coli (Ec) (SEQ ID NO: 2), Salmonella typhimurium (5W)(SEQ ID NO: 18), Salmonella choleraesuis (Sc) (SEQ ID NO: 19), Salmonella paratyphi (Spt) (SEQ ID NO: 20), Salmonella typhi (St) (SEQ ID NO: 21), Yersinis pestis (Yp) (SEQ ID NO: 22), Yersinis pseudotuberculosis (Ypt) (SEQ ID NO: 23), Shigella sonnei (Ss) (SEQ ID NO: 24), Shigella flexneri (Sf) (SEQ ID NO: 25).
  • Ec Escherichia coli
  • Ec Escherichia coli
  • Salmonella typhimurium 5W
  • Sc Salmonella choleraesuis
  • PtsG/Crr the glucose-specific PTS permease
  • PEP phosphoenolpyruvate
  • PTS sugar transporting phosphotransferase system
  • the PTS transports and simultaneously phosphorylates its sugar substrates in a process called group translocation.
  • PtsG/Crr takes up exogenous glucose, releasing the phosphate ester into the cell cytoplasm in preparation for metabolism, primarily via glycolysis.
  • the mutant IIB/IIC subunit of the glucose-specific PTS permease according to the present invention is one of the following:
  • (B) a variant of protein (A), which has an activity of glucose-specific PTS permease when combined with the HA (Crr) subunit.
  • the phrase "activity of glucose-specific PTS permease” means the activity of transporting and simultaneously phosphorylating its sugar substrates.
  • the activity of glucose-specific PTS permease can be detected by, for example, the method described by Postma, P. W. et al (Microbiol. Rev., 57, 3, 543-94 (1993)). It is estimated that the mutant IIB/IIC subunit of the present invention has an activity of glucose-specific PTS permease higher than that of the wild-type IIB/IIC subunit when combined with the HA subunit.
  • amino acid residues at positions 263 and/or 359 refers to the positions in the amino acid sequence of wild-type PtsG from E. coli, which is shown in SEQ ID NO: 2. However, these position may change. For example, if an amino acid residue is inserted in the N-terminus portion, the amino acid residue inherently located at position 263 becomes position 264. In such a case, the amino acid residue at original position 263 is the amino acid residue at position 263 in the present invention.
  • the mutant PtsG may include deletion, substitution, insertion, or addition of one or several amino acids at one or a plurality of positions other than at positions 263 and 359, provided that the glucose-specific PTS permease activity is not lost or reduced. Replacing the alanine at position 263 and the isoleucine at position 359 in SEQ ID NO: 2 with another amino acids is preferable.
  • Amino acids that may replace the Ala at position 263 include Arg, Asp, Asn, Cys, GIu, GIn 5 GIy, His, lie, Met, Leu, Lys, Phe, Ser, Trp, Tyr, VaI, Pro and Thr. Hydrophobic amino acids such as GIy, VaI, Leu, and He are preferable, and amino acids which have a branched chain, such as VaI, are more preferable.
  • Amino acids that may replace the He at position 359 include Ala, Arg, Asp, Asn, Cys, GIu, GIn 5 GIy 5 His, Met, Leu, Lys, Phe, Ser, Trp, Tyr, VaI, Pro, and Thr. Hydrophobic amino acids such as Ala, GIy, VaI, and Leu are preferable, and amino acids which have a branched chain such as Leu, VaI are more preferable.
  • mutant PtsG and mutant ptsG gene according to the present invention can be obtained from the wild-type ptsG gene by site-specific mutagenesis using known methods, such as PCR (polymerase chain reaction; refer to White, TJ. et al., Trends Genet., 5, 185 (1989)) utilizing primers based on the nucleotide sequence of the gene.
  • PCR polymerase chain reaction
  • the wild-type ptsG gene which encodes the IIB/IIC subunit of glucose-specific PTS permease (synonyms - Bl 101, TgI, Umg, UmgC, Gpt, Cat, Car, GIcA, PtsG) from Escherichia coli has been elucidated (nucleotide numbers from 1157092 to 1158525 in the sequence of GenBank accession NC_000913.2, gi: 49175990).
  • the ptsG gene is located between the >>c/?7 ORF aad ⁇ iuE gene on the chromosome of E. coli K-12.
  • the wild-type err gene which encodes the HA subunit of glucose-specific PTS permease (synonyms - B2417, TreD, Tgs, lex, Gsr, Crr) from Escherichia coli has been elucidated (nucleotide numbers from 2533856 to 2534365 in the sequence of GenBank accession NC_000913.2, gi: 49175990).
  • the crr gene is located between the ptsl and pdxK genes on the chromosome of E. coli K-12.
  • the nucleotide sequence of the crr gene is shown in SEQ ID NO: 13.
  • the amino acid sequence encoded by the nucleotide sequence is shown in SEQ ID NO: 14.
  • the ptsG and crr genes can be obtained by PCR (polymerase chain reaction; refer to White, TJ. et al, Trends Genet, 5, 185 (1989)) utilizing primers based on the known nucleotide sequence of the gene.
  • Genes coding for the HA, HB, HC subunits, and combinations thereof of the glucose-specific PTS permease from other microorganisms can be obtained in a similar manner.
  • the ptsG gene derived from Escherichia coli is exemplified by a DNA which encodes the following protein (A) or (B): (A) a protein which has the amino acid sequence shown in SEQ ID NO: 2; or
  • (B) a variant protein of the amino acid sequence shown in SEQ ID NO: 2, which has an activity of glucose-specific PTS permease when combined with the HA (Crr) subunit.
  • variant protein means a protein which has changes in the sequence, whether they are deletions, insertions, additions, or substitutions of amino acids, but still maintains the desired activity at a useful level, for example, useful for the enhanced production of an L-amino acid.
  • the number of changes in the variant protein depends on the position in the three dimensional structure of the protein or the type of amino acid residue. The number of changes may be 1 to 30, preferably 1 to 15, and more preferably 1 to 5 for the protein (A). These changes can occur in regions of the protein which are not critical for the function of the protein. This is because some amino acids have high homology to one another so the three dimensional structure or activity is not affected by such a change.
  • the protein variant (B) may be one which has a homology of not less than 70%, preferably not less than 80%, and more preferably not less than 90%, and most preferably not less than 95% with respect to the entire amino acid sequence of the IIB/IIC subunit of glucose-specific PTS permease shown in SEQ ID NO. 2, as long as the activity of glucose-specific PTS permease is maintained. Since glucose-specific PTS permease consists of IIB/IIC subunit encoded by ptsG gene and HA subunit encoded by crr gene, functional variant proteins (B) can be selected when Crr protein (HA subunit) is present and a complex of glucose-specific enzyme II (EII) transporter (II Glc ) is formed.
  • Homology between two amino acid sequences can be determined using the well- known methods, for example, the computer program BLAST 2.0, which calculates three parameters: score, identity, and similarity.
  • substitution, deletion, insertion, or addition of one or several amino acid residues should be conservative mutation(s) so that the activity is maintained.
  • the representative conservative mutation is a conservative substitution.
  • conservative substitutions include substitution of Ser or Thr for Ala, substitution of GIn, His or Lys for Arg, substitution of GIu, GIn, Lys, His or Asp for Asn, substitution of Asn, GIu or GIn for Asp, substitution of Ser or Ala for Cys, substitution of Asn, GIu, Lys, His, Asp or Arg for GIn, substitution of Asn, GIn, Lys or Asp for GIu, substitution of Pro for GIy, substitution of Asn, Lys, GIn, Arg or Tyr for His, substitution of Leu, Met, VaI or Phe for He, substitution of He, Met, VaI or Phe for Leu, substitution of Asn, GIu, GIn, His or Arg for Lys, substitution of He, Leu, VaI or Phe for Met, substitution of Trp,
  • the DNA which encodes substantially the same protein as the IIB/IIC subunit of glucose-specific PTS permease described above may be obtained, for example, by modifying the nucleotide sequence of the DNA encoding IIB/IIC subunit of glucose-specific PTS permease (SEQ ID NO: 1), for example, by means of site-directed mutagenesis so that one or more amino acid residues at a specified site is deleted, substituted, inserted, or added.
  • DNA modified as described above may be obtained by conventionally known mutation treatments.
  • Such treatments include hydroxylamine treatment of the DNA encoding proteins of present invention, or treatment of the bacterium containing the DNA with UV irradiation or a reagent such as N-methyl-N'-nitro-N- nitrosoguanidine or nitrous acid.
  • a DNA encoding substantially the same protein as IIB/IIC subunit of glucose-specific PTS permease can be obtained by expressing DNA having a mutation as described above in an appropriate cell, and investigating the activity of any expressed product.
  • a DNA encoding substantially the same protein as IIB/IIC subunit of glucose-specific PTS permease can also be obtained by isolating a DNA that is able to hybridize with a probe having a nucleotide sequence which contains, for example, the nucleotide sequence shown as SEQ ID NO: 1, under stringent conditions, and encodes a protein having glucose- specific PTS permease activity when combined with the HA (Crr) subunit.
  • stringent conditions are conditions under which so-called specific hybrids, for example, a hybrid having homology of not less than 60%, more preferably not less than 70%, further preferably not less than 80%, and still more preferably not less than 90%, and most preferably not less than 95% are formed, and non-specific hybrids, for example, a hybrid having homology lower than the above are not formed.
  • stringent conditions may be exemplified by conditions under which DNA is able to hybridize at a salt concentration equivalent to ordinary washing conditions in Southern hybridization, i.e., 1 x SSC, 0.1% SDS, preferably 0.1 x SSC, 0.1% SDS, at 60°C.
  • Duration of washing depends on the type of membrane used for blotting and, as a rule, what is recommended by the manufacturer. For example, recommended duration of washing for the Hybond N+ nylon membrane (Amersham) under stringent conditions is 15 minutes. Preferably, washing may be performed 2 to 3 times.
  • a partial sequence of the nucleotide sequence of SEQ ID NO: 1 can also be used as a probe.
  • Probes may be prepared by PCR using primers based on the nucleotide sequence of SEQ ID NO: 1, and a DNA fragment containing the nucleotide sequence of SEQ ID NO: 1 as a template.
  • the hybridization conditions for washing include, for example, 50°C, 2 x SSC and 0.1% SDS.
  • substitution, deletion, insertion, or addition of nucleotides as described above also includes mutations which naturally occur (mutant or variant), for example, due to variety in the species or genus of bacterium, and which contains the glucose-specific PTS permease.
  • L-amino acid-producing bacterium means a bacterium which has an ability to cause accumulation of an L-amino acid in a medium when the bacterium is cultured in the medium.
  • the L-amino acid-producing ability may be imparted or enhanced by breeding.
  • the phrase "L-amino acid-producing bacterium” as used herein also means a bacterium which is able to produce and cause accumulation of an L-amino acid in a culture medium in amount larger than a wild-type or parental strain of the bacterium, for example, E. coli, such as E.
  • L-amino acids include L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L- glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L- phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine. L- threonine is particularly preferred.
  • the Enterohacteriaceae family includes bacteria belonging to the genera Escherichia, Enterobacter, Erwinia, Klebsiella, Pantoea, Providencia, Salmonella, Serratia, Shigella, Morganella, etc.. Specifically, bacteria classified into the Enterobacteriaceae family according to the taxonomy used by the NCBI (National Center for Biotechnology Information) database
  • a bacterium belonging to the genus Escherichia or Pantoea is preferred.
  • the phrase "a bacterium belonging to the genus Escherichia” means that the bacterium is classified in the genus Escherichia according to the classification known to a person skilled in the art of microbiology. Examples of a bacterium belonging to the genus Escherichia as used in the present invention include, but are not limited to, Escherichia coli (E. coli).
  • the bacterium belonging to the genus Escherichia that can be used in the present invention is not particularly limited, however for example, bacteria described by Neidhardt, F.C. et al. (Escherichia coli and Salmonella typhimurium, American Society for Microbiology, Washington D. C, 1208, Table 1) are encompassed by the present invention.
  • a bacterium belonging to the genus Pantoea means that the bacterium is classified as the genus Pantoea according to the classification known to a person skilled in the art of microbiology.
  • Some species of Enterobacter agglomerans have been recently re- classified into Pantoea agglomerans, Pantoea ananatis, Pantoea stewartii, or the like, based on the nucleotide sequence analysis of 16S rRNA etc. (Int. J. Syst. Bacteriol., 43, 162-173 (1993)).
  • the bacterium of the present invention encompasses a strain of the Enterobacteriaceae family which has an ability to produce an L-amino acid and has been modified to contain mutant IIB/IIC subunit of glucose-specific PTS permease.
  • the strain which contains the mutant IIB/IIC subunit of glucose-specific PTS permease can be constructed by transformation with DNA encoding the mutant protein or introduction of the mutation into the native ptsG gene by homologous recombination.
  • the bacterium of the present invention encompasses a strain of the Enterobacteriaceae family wherein the glucose-specific PTS permease activity is enhanced by introduction of the mutant IIB/IIC subunit of glucose specific PTS permease.
  • the bacterium of the present invention encompasses a strain of the Enterobacteriaceae family wherein expression of the gene encoding the mutant IIB/IIC subunit is enhanced.
  • the strain contains the mutant glucose-specific PTS permease including the mutant IIB/IIC subunit and the wild- type IIA subunit.
  • the mutant glucose specific PTS permease has a higher activity than that of the wild type glucose specific PTS permease. Therefore, the activity of glucose-specific PTS permease activity of the bacterium of the present invention is higher when compared to that of a non-modified strain, for example, a wild-type strain.
  • expression of the gene encoding the mutant IIB/IIC subunit may be enhanced by increasing a copy number of the gene or modifying an expression regulating sequence of the gene.
  • a wild- type strain that may be used for comparison purposes includes, for example, Escherichia coli K- 12.
  • the amount of accumulated L-amino acid, for example, L-threonine can be increased in a culture medium as a result of enhancing the intracellular activity of glucose-specific PTS permease.
  • Enhancing glucose-specific PTS permease activity in a bacterial cell can be attained by introduction of the mutant ptsG gene encoding mutant IIB/IIC subunit of glucose- specific PTS permease.
  • expression of the gene is enhanced means that the expression of the gene is higher than that of a non-modified strain, for example, a wild-type strain.
  • modifications include increasing the copy number of expressed gene(s) per cell, increasing the expression level of the gene(s), and so forth.
  • the quantity of the copy number of an expressed gene is measured, for example, by restricting the chromosomal DNA followed by Southern blotting using a probe based on the gene sequence, fluorescence in situ hybridization (FISH), and the like.
  • FISH fluorescence in situ hybridization
  • the level of gene expression can be measured by various known methods including Northern blotting, quantitative RT-PCR, and the like.
  • the amount of the protein expressed by the gene can be measured by known methods including SDS-PAGE followed by immunoblotting assay (Western blotting analysis), and the like.
  • wild-type strains that can be used as a control include, for example, Escherichia coli K-12 or Pantoea ananatis FERM BP-6614.
  • L-amino acid accumulation for example L-threonine, accumulation in a medium is observed.
  • Transformation of a bacterium with DNA encoding a protein means introduction of the DNA into a bacterium, for example, by conventional methods. Transformation of this DNA will result in an increase in expression of the gene encoding the protein of present invention, and will enhance the activity of the protein in the bacterial cell. Methods of transformation include any known methods that have hitherto been reported. For example, a method of treating recipient cells with calcium chloride so as to increase permeability of the cells to DNA has been reported for Escherichia coli K- 12 (Mandel, M. and Higa, A., J. MoI. Biol, 53, 159 (1970)) and the like may be used.
  • Methods of gene expression enhancement include increasing the gene copy number. Introducing a gene into a vector that is able to function in a bacterium of the Enterobacteriaceae family increases the copy number of the gene.
  • low-copy vectors are used. Examples of low-copy vectors include but are not limited to pSClOl, pMWl 18, pMWl 19, and the like.
  • the term "low copy vector" is used for vectors, the copy number of which is up to 5 copies per cell.
  • Enhancement of gene expression may also be achieved by introduction of multiple copies of the gene into a bacterial chromosome by, for example, homologous recombination, such as by employing a linear DNA, which is known as "Red-driven integration" (Datsenko, K. A. and Wanner, B. L., Proc. Natl. Acad. Sci. USA, 97, 12, p 6640-6645 (2000)), Mu integration, or the like.
  • Red-driven integration a linear DNA
  • Mu integration or the like.
  • one act of Mu integration allows for introduction of up to 3 copies of the gene into a bacterial chromosome.
  • Increasing the copy number of the mutant glucose-specific PTS permease gene can also be achieved by introducing multiple copies of the mutant glucose-specific PTS permease gene into the chromosomal DNA of the bacterium.
  • homologous recombination is carried out using a sequence which exists in multiple copies as targets in the chromosomal DNA.
  • Sequences having multiple copies in the chromosomal DNA include, but are not limited to repetitive DNA, or inverted repeats existing at the end of a transposable element.
  • Enhancing gene expression may also be achieved by placing the DNA of the present invention under the control of an expression control sequence, such as a promoter, which is stronger than the native expression control sequence.
  • an expression control sequence such as a promoter
  • the P tac promoter, the lac promoter, the trp promoter, the trc promoter, the PR, or the PL promoters of lambda phage are all known to be potent promoters.
  • the use of a potent promoter can be combined with multiplication of gene copies.
  • the effect of a promoter can be enhanced by, for example, introducing a mutation into the promoter to increase the transcription level of a gene located downstream of the promoter.
  • the rhtA23 mutation is an A-for-G substitution at the -1 position relative to the ATG start codon (ABSTRACTS of 17 th International Congress of Biochemistry and Molecular Biology in conjugation with 1997 Annual Meeting of the American Society for Biochemistry and Molecular Biology, San Francisco, California August 24-29, 1997, abstract No. 457). Therefore, it may be suggested that the rhtA23 mutation enhances rhtA gene expression and, as a consequence, increases resistance to threonine, homoserine and some other substances which are transported out of the cells.
  • the alteration of the expression control sequence can be performed, for example, in the same manner as the gene substitution using a temperature-sensitive plasmid, as disclosed in International Patent Publication WO 00/18935 and Japanese Patent Application Laid-OpenNo. 1-215280.
  • Methods for preparation of plasmid DNA include, but are not limited to digestion and ligation of DNA, transformation, selection of an oligonucleotide as a primer and the like, or other methods well known to one skilled in the art. These methods are described, for instance, in Sambrook, J., Fritsch, E.F., and Maniatis, T., "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989).
  • the bacterium of the present invention can be obtained by introduction of the aforementioned DNAs into a bacterium which inherently has the ability to produce L- amino acid.
  • the bacterium of the present invention can be obtained by imparting an ability to produce L-amino acid to the bacterium already containing the DNAs.
  • the mutant IIB/IIC subunit produced in the bacterium which has the mutant ptsG gene forms the mutant glucose-specific PTS permease with the IIB/IIC subunit expressed from the wild type err gene which is inherently present in the bacterium.
  • expression of the mutant IIB/IIC subunit is enhanced, it is preferable that expression of the err gene encoding HA subunit is also enhanced.
  • introduction of both genes may be carried out separately by using different vectors or both of the genes may be carried on the same vector by using a single vector.
  • variant IIB/IIC subunit having the conservative mutations and mutant ptsG gene encoding the variant and method for enhancing expression of the mutant IIB/IIC subunit can be applied to HA subunit and err gene in the same way.
  • Examples of methods of attenuating expression of the native ptsG gene include mutating or deleting the gene. For example, this can be achieved by using recombination to inactivate the gene on the chromosome, or to modify an expression regulating sequence such as a promoter or the Shine-Dalgarno (SD) sequence (WO95/34672; Carrier, T.A. and Keasling, J.D., Biotechnol Prog 15, 58-64 (1999)).
  • SD Shine-Dalgarno
  • bacteria which are able to produce either an aromatic or a non-aromatic L-amino acids may be used.
  • the bacterium of the present invention can be obtained by modifying a bacterium which inherently has the ability to produce L-amino acids so that the bacterium contains the mutant glucose-specific PTS permease.
  • the bacterium of present invention can be obtained by imparting the ability to produce L-amino acids to a bacterium already containing the mutant glucose-specific PTS permease.
  • L-threonine-producing bacteria examples include, but are not limited to, L-threonine-producing bacteria belonging to the genus Escherichia, such as E. coli TDH-6/pVIC40 (VKPM B-3996) (US Patent 5,175,107 and US Patent 5,705,371), E. co/z NRRL-21593 (US Patent 5,939,307), E. coli FERM BP-3756 (US Patent 5,474,918), E. coli FERM BP-3519 and FERM BP-3520 (US Patent 5,376,538), E. coli MG442 (Gusyatiner et al., Genetika (in Russian), 1978, 14: 947- 956), E. coli VL643 and VL2055 (EP 1149911 A), and the like.
  • L-threonine-producing bacteria belonging to the genus Escherichia such as E. coli TDH-6/pVIC40 (VKPM B-3996)
  • the strain TDH-6 is deficient in the thrC gene, as well as being sucrose- assimilative, and the UvA gene has a leaky mutation. This strain also has a mutation in the rhtA gene, which imparts resistance to high concentrations of threonine or homoserine.
  • the strain B-3996 contains the plasmid pVIC40 which was obtained by inserting a thrA*BC operon which includes a mutant thrA gene into a RSFlOlO-derived vector. This mutant thrA gene encodes aspartokinase homoserine dehydrogenase I which has substantially desensitized feedback inhibition by threonine.
  • the strain B-3996 was deposited in the All- Union Scientific Center of Antibiotics (USD, 117105 Moscow, Nagatinskaya Street 3-A) on November 19, 1987 under accession number RIA 1867. The strain was also deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (USD, 117545 Moscow, 1 st Dorozhny proezd, 1) on April 7, 1987 under accession number VKPM B-3996.
  • VKPM Russian National Collection of Industrial Microorganisms
  • the bacterium of the present invention is further modified to enhance expression of one or more of the following genes:
  • mutant thrA gene which encodes aspartokinase homoserine dehydrogenase I resistant to feedback inhibition by threonine
  • thrB gene which encodes homoserine kinase
  • the thrA gene which encodes aspartokinase homoserine dehydrogenase I of Escherichia coli has been elucidated (nucleotide positions 337 to 2799, GenBank accession no. NC_000913.2, gi: 49175990).
  • the thrA gene is located between the thrL and thrB genes on the chromosome of E. coli K- 12.
  • the thrB gene which encodes homoserine kinase of Escherichia coli has been elucidated (nucleotide positions 2801 to 3733, GenBank accession no. NC_000913.2, gi: 49175990).
  • the thrB gene is located between thrA and thrC genes on the chromosome of E. coli K-12.
  • the thrC gene which encodes threonine synthase of Escherichia coli has been elucidated (nucleotide positions 3734 to 5020, GenBank accession no. NC_000913.2, gi: 49175990).
  • the thrC gene is located between the thrB gene and the yaaX open reading frame on the chromosome of E. coli K- 12. All three genes function as a single threonine operon.
  • a mutant thrA gene which encodes aspartokinase homoserine dehydrogenase I resistant to feedback inhibition by threonine, as well as the thrB and thrC genes, can be obtained as one operon from the well-known plasmid pVIC40 which is present in the threonine producing E. coli VKPM B-3996. Plasmid pVIC40 is described in detail in US Patent 5,705,371.
  • the rhtA gene exists at 18 min on the E. coli chromosome close to the glnHPQ operon, which encodes components of the glutamine transport system.
  • the rhtA gene is identical to ORFl (ybiF gene, positions 764 to 1651, GenBank accession no. AAA218541, gi:440181) and located between the pexB and ompX genes.
  • the unit expressing a protein encoded by the ORFl has been designated the rhtA gene (rht: resistance to homoserine and threonine).
  • the asd gene of E. coli has already been elucidated (nucleotide positions 3572511 to 3571408, GenBank accession no. NC_000913.1, gi:16131307), and can be obtained by PCR (polymerase chain reaction; refer to White, TJ. et al., Trends Genet., 1989, 5:185), utilizing primers based on the nucleotide sequence of the gene.
  • the asd genes of other microorganisms can be obtained in a similar manner.
  • the aspC gene of E. coli has already been elucidated (nucleotide positions 983742 to 984932, GenBank accession no. NC_Q00913.1, gi:16128895), and can be obtained by PCR.
  • the aspC genes of other microorganisms can be obtained in a similar manner.
  • L-lysine-producing bacteria examples include mutants having resistance to an L-lysine analogue.
  • the L-lysine analogue inhibits growth of bacteria belonging to the genus Escherichia, but this inhibition is fully or partially desensitized when L-lysine is present in a medium.
  • Examples of the L-lysine analogue include, but are not limited to, oxalysine, lysine hydroxamate, S-(2-aminoethyl)- L-cysteine (AEC), S-methyllysine, ⁇ -chlorocaprolactam, and so forth.
  • Mutants having resistance to these lysine analogues can be obtained by subjecting bacteria belonging to the genus Escherichia to a conventional artificial mutagenesis treatment.
  • bacterial strains useful for producing L-lysine include Escherichia coli AJl 1442 (FERM BP-1543, NRRL B-12185; see U.S. Patent 4,346,170) and Escherichia coli VL611. In these microorganisms, feedback inhibition of aspartokinase by L-lysine is desensitized.
  • the strain WC 196 may be used as an L-lysine producing bacterium of Escherichia coli. This bacterial strain was bred by conferring the AEC resistance to strain W3110, which was derived from Escherichia coli K- 12. The resulting strain was designated Escherichia coli AJ13069 and was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (currently National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on December 6, 1994 and received an accession number of FERM P- 14690. Then, it was converted to an international deposit under the provisions of the Budapest Treaty on September 29, 1995, and received an accession number of FERM BP-5252 (US Patent 5,827,698).
  • Examples of parent strains for deriving L-lysine-producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L- lysine biosynthetic enzyme are enhanced.
  • genes include, but are not limited to, genes encoding dihydrodipicolinate synthase (dapA), aspartokinase (fysC), dihydrodipicolinate reductase (dapB), diaminopimelate decarboxylase (IysA), diaminopimelate dehydrogenase (ddh) (U.S. Patent No.
  • ppc phosphoenolpyrvate carboxylase
  • aspartate semialdehyde dehydrogenase aspartate semialdehyde dehydrogenase
  • aspartase aspartase
  • the parent strains may have increased expression of the gene involved in energy efficiency (cyo) (EP 1170376 A), the gene encoding nicotinamide nucleotide transhydrogenase (pntAB) (U.S. Patent No. 5,830,716), the ybjE gene (WO2005/073390), or combinations thereof.
  • parent strains for deriving L-lysine-producing bacteria of the present invention also include strains having decreased or eliminated activity of an enzyme that catalyzes a reaction for generating a compound other than L-lysine by branching off from the biosyntlietic pathway of L-lysine.
  • examples include homoserine dehydrogenase, lysine decarboxylase (U.S. Patent No. 5,827,698), and the malic enzyme (WO2005/010175).
  • Examples of parent strains for deriving the L-cysteine-producing bacteria of the present invention include, but are not limited to, L-cysteine-producing bacteria belonging to the genus Escherichia, such as E. colt JMl 5, which is transformed with different cysE alleles encoding feedback-resistant serine acetyltransferases (US Patent 6,218,168, Russian patent application 2003121601); E. coli W3110 having over-expressed genes which encode proteins suitable for secreting substances toxic for cells (US Patent 5,972,663); E. coli strains having lowered cysteine desulfohydrase activity (JP 11-15557 IA); E. coli W3110 with increased activity of a positive transcriptional regulator for cysteine regulon encoded by the cysB gene (WOO 127307 'A 1 ), and the like.
  • L-cysteine-producing bacteria belonging to the genus Escherichia such as E. colt JMl 5,
  • parent strains for deriving the L-leucine-producing bacteria of the present invention include, but are not limited to, L-leucine-producing bacteria belonging to the genus Escherichia, such as E. coli strains resistant to leucine analogs, including ⁇ -2- thienylalanine, 3-hydroxyleucine, 4-azaleucine, and 5,5,5-trifluoroleucine (JP 62-34397B and JP 08-70879 A); E. coli strains obtained by the gene-engineering method described in WO96/06926; E. coli H-9068 (JP 08-70879A), and the like.
  • L-leucine-producing bacteria belonging to the genus Escherichia such as E. coli strains resistant to leucine analogs, including ⁇ -2- thienylalanine, 3-hydroxyleucine, 4-azaleucine, and 5,5,5-trifluoroleucine (JP 62-34397B and JP 08-708
  • the bacterium of the present invention may be improved by enhancing the expression of one or more genes involved in L-leucine biosynthesis.
  • genes of the leuABCD operon which are preferably represented by the mutant leuA gene encoding isopropylmalate synthase freed from feedback inhibition by L-leucine (US Patent 6,403,342).
  • the bacterium of the present invention may be improved by enhancing the expression of one or more genes encoding proteins which secrete L-amino acid from the bacterial cell. Examples of such genes include the b2682 and b2683 genes (ygaZH genes, EP1239041 A2). L-histidine-producing bacteria
  • Examples of parent strains for deriving the L-histidine-producing bacteria of the present invention include, but are not limited to, L-histidine-producing bacteria belonging to the genus Escherichia, such as E. coli strain 24 (VKPM B-5945, RU2003677); E. coli strain 80 (VKPM B-7270, RU2119536); E. coli NRRL B-12116 - B12121 (US Patent 4,388,405); E. coli H-9342 (FERM BP-6675) and H-9343 (FERM BP-6676) (US Patent 6,344,347); E. coli H-9341 (FERM BP-6674) (EP1085087); E. coli AI80/pFM201 (US Patent 6,258,554), and the like.
  • E. coli strain 24 VKPM B-5945, RU2003677
  • E. coli strain 80 VKPM B-7270, RU2119536
  • Examples of parent strains for deriving L-histidine-producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L-histidine biosynthetic enzyme are enhanced.
  • examples of such genes include genes encoding ATP phosphoribosyltransferase (MsG), phosphoribosyl AMP cyclohydrolase (MsI), phosphoribosyl-ATP pyrophosphohydrolase (hisIE), phosphoribosylformimino-5- arninoimidazole carboxamide ribotide isomerase (MsA), amidotransferase (MsH), histidinol phosphate aminotransferase (hisC), histidinol phosphatase (hisB), histidinol dehydrogenase (MsD), and so forth.
  • MsG ATP phosphoribosyltransferase
  • MsI phosphoribosyl
  • L-histidine biosynthetic enzyme encoded by MsG and hisBHAFI are inhibited by L-histidine, and therefore an L-histidine-producing ability can also be efficiently enhanced by introducing a mutation conferring resistance to the feedback inhibition into ATP phosphoribosyltransferase (hisG) ( Russian Patent Nos. 2003677 and 2119536).
  • strains having an L-histidine-producing ability include E. coli FERM P-5038 and 5048 which have been introduced with a vector carrying a DNA encoding an L-histidine-biosynthetic enzyme (JP 56-005099 A), E. coli strains introduced with rht, a gene for an amino acid-export (EPl 01671 OA), E. coli 80 strain imparted with sulfaguanidine, DL-l,2,4-triazole-3-alanine, and streptomycin-resistance (VKPM B-7270, Russian Patent No. 2119536), and so forth.
  • Examples of parent strains for deriving the L-glutamic acid-producing bacteria of the present invention include, but are not limited to, L-glutamic acid-producing bacteria belonging to the genus Escherichia, such as E. coli VL334thrC + (EP 1172433).
  • E. coli VL334 (VKPM B-1641) is an L-isoleucine and L-threonine auxotrophic strain having mutations in the thrC and HvA genes (US Patent 4,278,765).
  • a wild-type allele of the thrC gene was transferred by the method of general transduction, using bacteriophage Pl grown on wild-type E. coli Kl 2 (VKPM B-7) cells.
  • an L-isoleucine auxotrophic strain VL334thrC + (VKPM B-8961) was obtained. This strain is able to produce L-glutamic acid.
  • parent strains for deriving the L-glutamic acid-producing bacteria of the present invention include, but are not limited to, strains in which expression of one or more genes encoding an L-glutamic acid biosynthetic enzyme are enhanced.
  • genes include genes encoding glutamate dehydrogenase (gdh), glutamine synthetase (glnA), glutamate synthetase (gltAB), isocitrate dehydrogenase (icdA), aconitate hydratase (acnA, acnB), citrate synthase (gltA), phosphoenolpyruvate carboxylase (ppc), pyruvate carboxylase (pyc), pyruvate dehydrogenase (aceEF, ipdA), pyruvate kinase (pykA, pykF), phosphoenolpyruvate synthase (ppsA), enolase
  • strains modified so that expression of the citrate synthetase gene, the phosphoenolpyruvate carboxylase gene, and/or the glutamate dehydrogenase gene is/are enhanced include those disclosed in EP1078989A, EP955368A, and EP952221A.
  • Examples of parent strains for deriving the L-glutamic acid-producing bacteria of the present invention also include strains having decreased or eliminated activity of an enzyme that catalyzes synthesis of a compound other than L-glutamic acid, and branching off from an L-glutamic acid biosynthesis pathway.
  • Such enzymes include isocitrate lyase (aceA), ⁇ -ketoglutarate dehydrogenase (sucA), phosphotransacetylase (ptd), acetate kinase (act), acetohydroxy acid synthase (UvG), acetolactate synthase (JIvI), formate acetyltransferase (pfl), lactate dehydrogenase (Idh), and glutamate decarboxylase (gadAB).
  • aceA isocitrate lyase
  • sucA ⁇ -ketoglutarate dehydrogenase
  • ptd phosphotransacetylase
  • act acetohydroxy acid synthase
  • UvG acetolactate synthase
  • JIvI formate acetyltransferase
  • Idh lactate dehydrogenase
  • glutamate decarboxylase gadAB
  • E. coli W3110sucA::Kmr is obtained by disrupting the ⁇ -ketoglutarate dehydrogenase gene (hereinafter referred to as "sue A gene") of E. coli W3110. This strain is completely deficient in ⁇ -ketoglutarate dehydrogenase.
  • L-glutamic acid-producing bacterium examples include those which belong to the genus Escherichia and have resistance to an aspartic acid antimetabolite. These strains can also be deficient in the ⁇ -ketoglutarate dehydrogenase activity and include, for example, E. coli AJ13199 (FERM BP-5807) (U.S. Patent No. 5.908,768), FFRM P-12379, which additionally has a low L-glutamic acid decomposing ability (U.S. Patent No. 5,393,671); AJ13138 (FERM BP-5565) (U.S. Patent No. 6,110,714), and the like.
  • L-glutamic acid-producing bacteria include mutant strains belonging to the genus Pantoea which are deficient in ⁇ -ketoglutarate dehydrogenase activity or have a decreased ⁇ -ketoglutarate dehydrogenase activity, and can be obtained as described above.
  • Such strains include Pantoea ananatis AJ13356. (US Patent 6,331,419).
  • Pantoea ananatis AJl 3356 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on February 19, 1998 under accession no. FERM P- 16645. It was then converted to an international deposit under the provisions of Budapest Treaty on January 11, 1999 and received accession no. FERM BP- 6615.
  • Pantoea ananatis AJ13356 is deficient in ⁇ -ketoglutarate dehydrogenase activity as a result of disruption of the ⁇ KGDH-El subunit gene ⁇ sue A).
  • the above strain was identified as Enterobacter agglomerans when it was isolated and deposited as Enterobacter agglomerans AJl 3356.
  • Pantoea ananatis on the basis of nucleotide sequencing of 16S rRNA and so forth.
  • AJ13356 was deposited at the aforementioned depository as Enterobacter agglomerans, for the purposes of this specification, they are described as Pantoea ananatis.
  • Examples of parent strains for deriving the L-phenylalanine-producing bacteria of the present invention include, but are not limited to, L-phenylalanine-producing bacteria belonging to the genus Escherichia, such as E. coli AJ12739 (tyrA::TnlO, tyrR) (VKPM B-8197); E. coli HW1089 (ATCC 55371) harboring the pheA34 gene (U.S. Patent 5,354,672); K coli MWEC101-b (KR8903681); E. col ⁇ NRBL B-12141, NRRL B-12145, NRRL B-12146, and NRRL B-12147 (U.S. Patent 4,407,952).
  • L-phenylalanine-producing bacteria belonging to the genus Escherichia such as E. coli AJ12739 (tyrA::TnlO, tyrR) (VKPM B-8197); E. coli HW1089 (AT
  • E. coli K-12 [W3110 (tyrA)/pPHAB (FERM BP-3566), E. coli K-12 [W3110 (tyrA)/pPHAD] (FERM BP-12659), E. coli K-12 [W3110 (tyrA)/pPHATerm] (FERM BP-12662), and E. coli K-12 [W3110 (tyrA)/pBR-aroG4, pACMAB] named AJ 12604 (FERM BP-3579) may be used (EP 488424 Bl).
  • L-phenylalanine-producing bacteria belonging to the genus Escherichia with an enhanced activity of the protein encoded by HheyedA gene or the yddG gene may also be used (US patent applications 2003/0148473 Al and 2003/0157667 Al).
  • Examples of parent strains for deriving the L-tryptophan-producing bacteria of the present invention include, but are not limited to, L-tryptophan-producing bacteria belonging to the genus Escherichia, such as E. coli JP4735/pMU3028 (DSM10122) and JP6015/pMU91 (DSM10123) deficient in tryptophanyl-tRNA synthetase encoded by a mutant trpS gene (US Patent 5,756,345); E. coli SVl 64 (pGH5) having the serA allele free from feedback inhibition by serine (US Patent 6,180,373); E.
  • L-tryptophan-producing bacteria belonging to the genus Escherichia such as E. coli JP4735/pMU3028 (DSM10122) and JP6015/pMU91 (DSM10123) deficient in tryptophanyl-tRNA synthetase encoded by a mutant trpS gene (US Patent
  • the yddG gene encodes a membrane protein which is not involved in a biosynthetic pathway of any L-amino acid, and imparts to a microorganism resistance to L-phenylalanine and several amino acid analogues when the wild-type allele of the gene is amplified on a multi-copy vector in the microorganism.
  • Hh ⁇ yddG gene can enhance production of L-phenylalanine or L-tryptophan when additional copies are introduced into the cells of the respective producing strain (WO03044192). So it is desirable that the L-tryptophan-producing bacterium be further modified to have enhanced expression of the yddG open reading frame.
  • Examples of parent strains for deriving the L-tryptophan-producing bacteria of the present invention also include strains in which one or more activities of the enzymes selected from anthranilate synthase, phosphoglycerate dehydrogenase, and tryptophan synthase are enhanced.
  • the anthranilate synthase and phosphoglycerate dehydrogenase are both subject to feedback inhibition by L-tryptophan and L-serine, so that a mutation desensitizing the feedback inhibition may be introduced into these enzymes.
  • Specific examples of strains having such a mutation include an E. coli SV 164 which harbors desensitized anthranilate synthase and a transformant strain obtained by introducing into the E. coli SVl 64 the plasmid pGH5 (WO 94/08031), which contains a mutant serA gene encoding feedback-desensitized phosphoglycerate dehydrogenase.
  • Examples of parent strains for deriving the L-tryptophan-producing bacteria of the present invention also include strains into which the tryptophan operon which contains a gene encoding desensitized anthranilate synthase has been introduced (JP 57-71397 A, JP 62-244382 A, U.S. Patent No. 4,371,614).
  • L-tryptophan-producing ability may be imparted by enhancing expression of a gene which encodes tryptophan synthase, among tryptophan operons (trpBA).
  • the tryptophan synthase consists of ⁇ and ⁇ subunits which are encoded by trpA and trpB, respectively.
  • L-tryptophan-producing ability may be improved by enhancing expression of the isocitrate lyase-malate synthase operon (WO2005/103275).
  • Examples of parent strains for deriving the L-proline-producing bacteria of the present invention include, but are not limited to, L-proline-producing bacteria belonging to the genus Escherichia, such as E. coli 702ilvA (VKUPM B-8012) which is deficient in the UvA gene, and is able to produce L-proline (EP 1172433).
  • the bacterium of the present invention may be improved by enhancing the expression of one or more genes involved in L-proline biosynthesis. Examples of such genes for L-proline-producing bacteria include iheproB gene encoding glutamate kinase, which has feedback inhibition by L-proline desensitized (DE Patent 3127361).
  • the bacterium of the present invention may be improved by enhancing the expression of one or more genes encoding proteins excreting L-amino acid from a bacterial cell.
  • genes are exemplified by the b2682 and b2683 genes (ygaZH genes) (EP1239041 A2).
  • bacteria belonging to the genus Escherichia which have an activity to produce L-proline, include the following E. coli strains: NRRL B- 12403 and NRRL B- 12404 (GB Patent 2075056), VKPM B-8012 (Russian patent application 2000124295), plasmid mutants described in DE Patent 3127361, plasmid mutants described by Bloom F.R. et al (The 15 th Miami winter symposium, 1983, p.34) s and the like.
  • Examples of parent strains for deriving the L-arginine-producing bacteria of the present invention include, but are not limited to, L-arginine-producing bacteria, such as E. coli strain 237 (VKPM B-7925) (US Patent Application US2002058315) and its derivative strains harboring mutant N-acetylglutamate synthase ( Russian Patent Application No. 2001112869), E. coli strain 382 (VKPM B-7926) (EP1170358A1), an arginine-producing strain which has the argA gene encoding N-acetylglutamate synthetase introduced therein (JP 57-5693A), and the like.
  • L-arginine-producing bacteria such as E. coli strain 237 (VKPM B-7925) (US Patent Application US2002058315) and its derivative strains harboring mutant N-acetylglutamate synthase (Russian Patent Application No. 2001112869), E. coli strain 382 (VKPM B
  • Examples of parent strains for deriving L-arginine producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L- arginine biosynthetic enzyme are enhanced.
  • examples of such genes include genes encoding N-acetylglutamyl phosphate reductase (argC), ornithine acetyl transferase (argJ), N-acetylglutamate kinase (argB), acetylornithine transaminase (argD), ornithine carbamoyl transferase ⁇ argF), argininosuccinic acid synthetase (argG), argininosuccinic acid lyase (argH), and carbamoyl phosphate synthetase (car AB).
  • argC N-acetylglutamyl phosphate reductase
  • argJ ornithine acetyl transfer
  • Example of parent strains for deriving L-valine-producing bacteria of the present invention include, but are not limited to, strains which have been modified to overexpress the UvGMEDA operon (U.S. Patent No. 5,998,178). It is desirable to remove the region of the HvGMEDA operon which is required for attenuation so that expression of the operon is not attenuated by L- valine that is produced. Furthermore, the UvA gene in the operon is desirably disrupted so that threonine deaminase activity is decreased.
  • parent strains for deriving L-valine-producing bacteria of the present invention include also include mutants having a mutation of amino-acyl t-RNA synthetase (U.S. Patent No. 5,658,766).
  • E. coli VL1970 which has a mutation in the HeS gene encoding isoleucine tRNA synthetase, can be used.
  • E. coli VL 1970 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 113545 Moscow, 1 Dorozhny Proezd, 1) on June 24, 1988 under accession number VKPM B-4411.
  • mutants requiring lipoic acid for growth and/or lacking H + -ATPase can also be used as parent strains (WO96/06926).
  • parent strains for deriving L-isoleucine producing bacteria of the present invention include, but are not limited to, mutants having resistance to 6- dimethylaminopurine (JP 5-304969 A), mutants having resistance to an isoleucine analogue such as thiaisoleucine and isoleucine hydroxamate, and mutants additionally having resistance to DL-ethionine and/or arginine hydroxamate (JP 5-130882 A).
  • recombinant strains transformed with genes encoding proteins involved in L- isoleucine biosynthesis can also be used as parent strains (JP 2-458 A, FR 0356739, and U.S. Patent No. 5,998,178).
  • the method of the present invention is a method for producing an L-amino acid comprising cultivating the bacterium of the present invention in a culture medium to produce and excrete the L-amino acid into the medium, and collecting the L-amino acid from the medium.
  • the cultivation, collection, and purification of an L-amino acid from the medium and the like may be performed in a manner similar to conventional fermentation methods wherein an amino acid is produced using a bacterium.
  • a medium used for culture may be either a synthetic or natural medium, so long as the medium includes a carbon source and a nitrogen source and minerals and, if necessary, appropriate amounts of nutrients which the bacterium requires for growth.
  • the carbon source may include various carbohydrates such as glucose and sucrose, and various organic acids. Depending on the mode of assimilation of the used microorganism, alcohol, including ethanol and glycerol, may be used.
  • As the nitrogen source various ammonium salts such as ammonia and ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean-hydrolysate, and digested fermentative microorganism can be used.
  • the cultivation is preferably performed under aerobic conditions, such as a shaking culture, and a stirring culture with aeration, at a temperature of 20 to 40 0 C, preferably 30 to 38 0 C.
  • the pH of the culture is usually between 5 and 9, preferably between 6.5 and 7.2.
  • the pH of the culture can be adjusted with ammonia, calcium carbonate, various acids, various bases, and buffers. Usually, a 1 to 5-day cultivation leads to accumulation of the target L-amino acid in the liquid medium.
  • solids such as cells can be removed from the liquid medium by centrifugation or membrane filtration, and then the L-amino acid can be collected and purified by ion-exchange, concentration, and/or crystallization methods.
  • Example 1 Preparation of the E. coli strain TGl ⁇ ptsG ⁇ manXYZ.
  • E. coli strain TGl ⁇ ptsG was constructed by inactivation of the native ptsG gene in E. coli strain TGl by introducing the cat gene.
  • Cm R chloramphenicol resistance marker
  • the recombinant plasmid pKD46 (Datsenko, K.A., Wanner, B.L., Proc.Natl.Acad.Sci.USA, 2000, 97, 6640- 6645) with the thermosensitive replicon was used as the donor of the phage ⁇ -derived genes responsible for the Red-mediated recombination system.
  • Escherichia coli strain BW25113 containing the recombinant plasmid pKD46 can be obtained from the E. coli Genetic Stock Center, Yale University, New Haven, USA, the accession number of which is CGSC7630.
  • a DNA fragment containing a Cm R marker encoded by cat gene was obtained by PCR using the commercially available plasmid pACYC184 (GenBank/EMBL accession number X06403, "Fermentas", Lithuania) as the template, and primers Pl (SEQ ID NO: 3) and P2 (SEQ ID NO: 4).
  • Primer Pl contains 38 nucleotides homologous to the 5'-region of the ptsG gene introduced into the primer for further integration into the bacterial chromosome.
  • Primer P2 contains 41 nucleotides complementary to the 3 '-region of the ptsG gene introduced into the primer for further integration into the bacterial chromosome.
  • PCR was provided using the "Gene Amp PCR System 2700" amplificatory (Applied Biosystems).
  • the reaction mixture (total volume - 50 ⁇ l) consisted of 5 ⁇ l of 10x PCR- buffer with 25 mM MgCl 2 ("Fermentas", Lithuania), 200 ⁇ M each of dNTP, 25 pmol each of the exploited primers and 1 U of Taq-polymerase ("Fermentas", Lithuania).
  • Approximately 5 ng of the plasmid DNA was added to the reaction mixture as a template DNA for the PCR amplification.
  • the temperature profile was the following: initial DNA denaturation for 5 min at 95 °C, followed by 25 cycles of denaturation at 95 °C for 30 sec, annealing at 55 0 C for 30 sec, elongation at 72 °C for 40 sec; and the final elongation for 5 min at +72 °C. Then, the amplified DNA fragment was purified by agarose gel- electrophoresis, extracted using "GenElute Spin Columns" ("Sigma", USA) and precipitated by ethanol.
  • the obtained DNA fragment was used for electroporation and Red-mediated integration into the bacterial chromosome of the E. coli strain TGl/pKD46.
  • the grown cells from 10 ml of the bacterial culture were washed 3 times by the ice-cold de-ionized water, followed by suspending in 100 ⁇ l of the water. 10 ⁇ l of DNA fragment (100 ng) dissolved in the de-ionized water was added to the cell suspension.
  • the electroporation was performed by "Bio-Rad” electroporator (USA) (No. 165-2098, version 2-89) according to the manufacturer's instructions.
  • the temperature profile follows: initial DNA denaturation for 5 min at 95 0 C; then 30 cycles of denaturation at 95 0 C for 30 sec, annealing at 55 °C for 30 sec and elongation at 72 0 C for 1 min; the final elongation for 5 min at 72 0 C.
  • a few Cm R colonies tested contained the desired 1200 bp DNA fragment, confirming the presence of Cm R marker DNA instead of 1840 bp fragment of native ptsG gene.
  • One of the obtained strains was cured from the thermosensitive plasmid pKD46 by culturing at 37 0 C and the resulting strain was named as E. coli strain TGl ⁇ ptsG.
  • E. coli strain TGl ⁇ ptsG ⁇ man was constructed by inactivation of the native manXYZ operon in E. coli strain TGl ⁇ pts by introducing the kan gene. Nucleotide sequences of manX, manY and manZ genes are shown in the SEQ ID NOS: 15, 16 and 17, respectively.
  • the DNA fragment carrying the kanamicin resistance marker (Km R ) encoded by the kan gene was integrated into the chromosome of the E. coli strain TGl ⁇ pts in place of the native operon by the method described by Datsenko K.A. and Wanner B.L. (Proc.Natl.Acad.Sci.USA, 2000, 97, 6640-6645) which is also called as a "Red-mediated integration" and/or "Red-driven integration".
  • the recombinant plasmid pKD46 (Datsenko, K.A., Wanner, B.L., Proc.Natl.Acad.Sci.USA, 2000, 97, 6640-6645) with the thermosensitive replicon was used as the donor of the phage ⁇ -derived genes responsible for the Red-mediated recombination system.
  • Escherichia coli strain BW25113 containing the recombinant plasmid pKD46 can be obtained from the E. coli Genetic Stock Center, Yale University, New Haven, USA, the accession number of which is CGSC7630.
  • a DNA fragment containing a Km R marker encoded by the kan gene was obtained by PCR using the commercially available plasmid pACYC177 (GenBank/EMBL accession number X06402, "Fermentas", Lithuania) as the template, and primers P5 (SEQ ID NO: 7) and P6 (SEQ ID NO: 8).
  • Primer P5 contains 40 nucleotides homologous to the 5'-region of the manX gene introduced into the primer for further integration into the bacterial chromosome.
  • Primer P6 contains 41 nucleotides complementary to the 3 '-region of the manZgfas, introduced into the primer for further integration into the bacterial chromosome.
  • PCR was provided using the "Gene Amp PCR System 2700" amplificatory (Applied Biosystems).
  • the reaction mixture (total volume - 50 ⁇ l) consisted of 5 ⁇ l of 1Ox PCR- buffer with 25 mM MgCl 2 ("Fermentas", Lithuania), 200 ⁇ M each of dNTP, 25 pmol each of the exploited primers and 1 U of Taq-polymerase ("Fermentas", Lithuania). Approximately 5 ng of the plasmid DNA was added in the reaction mixture as a template DNA for the PCR amplification.
  • the temperature profile was the following: initial DNA denaturation for 5 min at 95 °C, followed by 25 cycles of denaturation at 95 °C for 30 sec, annealing at 55 °C for 30 sec, elongation at 72 0 C for 50 sec; and the final elongation for 5 min at +72 °C. Then, the amplified DNA fragment was purified by agarose gel- electrophoresis, extracted using "GenElute Spin Columns" ("Sigma", USA) and precipitated by ethanol.
  • the obtained DNA fragment was used for electroporation and Red-mediated integration into the bacterial chromosome of the E. coli strain TGl ⁇ ptsG/pKD46.
  • the temperature profile follows: initial DNA denaturation for 5 min at 95 0 C; then 30 cycles of denaturation at 95 0 C for 30 sec, annealing at 55 °C for 30 sec and elongation at 72 0 C for 45 sec; the final elongation for 5 min at 72 0 C.
  • a few Km R colonies tested contained the desired ⁇ 1065 bp DNA fragment, confirming the presence of Cm R marker DNA instead of -2780 bp fragment of manXYZ operone.
  • One of the obtained strains was cured from the thermosensitive plasmid pKD46 by culturing at 37 0 C and the resulting strain was named E. coli TGl ⁇ ptsG ⁇ manXYZ.
  • Example 2 Preparing mutant ystG gene.
  • the wild type ptsG (ptsG-wt) gene and the mutant ptsG (ptsG-mut) gene were obtained by PCR with using primers P9 (SEQ ID NO: 11) and PlO (SEQ ID NO: 12).
  • the mutant type ptsG gene was obtained by PCR under error-prone conditions.
  • Primer Pl contains a BamHl recognition site at the 5 '-end thereof, and primer P2 contains an EcoRl recognition site at the 3 '-end thereof which are necessary for further cloning of ptsG genes.
  • PCR was provided using the "Gene Amp PCR System 2700" amplificatory (Applied Biosystems).
  • the reaction mixture (total volume - 50 ⁇ l) consisted of 5 ⁇ l of 1Ox PCR- buffer, 2.5 mM MgCl 2 (for ptsG-wt) or 2.0 mM MnCl 2 (for ptsG-mut), 5 ⁇ M of dNTP mixture (2.5 mM each), 25 pmol each of the exploited primers and 1 U of AccuTaq - polymerase ("Sigma", USA). Approximately 20 ng of the E. coli MGl 655 genomic DNA was added to the reaction mixtures as a template DNA for the PCR amplification.
  • the temperature profile was the following: initial DNA denaturation for 5 min at 95 °C, followed by 35 cycles of denaturation at 95 0 C for 30 sec, annealing at 55 0 C for 30 sec, elongation at 72 0 C for 1 min; and the final elongation for 5 min at +72 °C. Then, the amplified DNA fragments were purified by agarose gel-electrophoresis, extracted using "GenElute Spin Columns" ("Sigma", USA) and precipitated by ethanol.
  • Both of the obtained fragments were digested by BamHl and EcoRl and cloned into pMWl 18/ BamHl- EcoRl vector, resulting in plasmid pMWl 18-ptsG-wt and set of plasmids pMWl 18-ptsG-mut accordingly.
  • strains TGl ⁇ ptsG ⁇ man / pMWl 18-ptsG-mut, containing plasmids with mutant ptsG gene were selected on the M9-plates (ampicillin (100 ⁇ g/ml), glucose 0.4%, casaminoacids 0.2%). Then clones grown on plates with 0.4% glucose were picked on M9- plates (ampicillin, mannose 0.4 %, casaminoacids 0.2%). Strains with good growth on plates with both sugars were tested on M9-medium with 0.4% glucose and on the M9 medium with 0.4% mannose (table 2).
  • the strain TGl ⁇ ptsG ⁇ man / pMWl 18- ⁇ tsG-43 was chosen, since its doubling time on glucose and on mannose was less than for the strain carryings the plasmid pt$G-vrt. Table 2.
  • the ptsG-wt gene was sequenced and native sequence of gene was confirmed.
  • the ptsG-mut-43 gene was sequenced and mutations were found: Ala263Val and Ile359Leu in SEQ ID NO:2 .
  • Example 3 The effect of introduction of the mutant ptsG gene on L-threonine production.
  • strain B-3996 was transformed with plasmid pMWl 18-ptsG-mut or pMWl 18- ptsG-wt.
  • the resulting strains, B-3996/ pMWl 18-ptsG-mut-43 and strain B-3996/ pMWl 18- ptsG-wt were each cultivated at 37 0 C for 18 hours in a nutrient broth and 0.3 ml of each of the obtained cultures was inoculated into 3 ml of fermentation medium having the following composition in a 20x200 mm test tube and cultivated at 37 0 C for 48 hours with a rotary shaker.
  • MgSO 4 -TH 2 O and CaCO 3 were each sterilized separately.
  • strain B3996/ pMWl 18-ptsG-mut-43 was able to cause accumulation of a higher amount of L-threonine as compared with B3996/ pMW118-ptsG-wt.
  • Example 4 The effect of introduction of the mutant ptsG gene on L-lysine production.
  • strain AJl 1442 can be transformed with plasmid pMWl 18-ptsG-mut or pMWl 18-ptsG-wt.
  • the strain AJl 1442 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, the independent administrative corporation, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Tsukuba Central 6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, postal code: 305-8566) on May 1, 1981, and received an accession number of FERM P-5084. Then, it was converted from the above original deposit to an international deposit under the provisions of the Budapest Treaty on October 29, 1987 and received an accession number of FERM BP- 1543.
  • Both E. coli strains can be cultured in L-medium at 37 0 C, and 0.3 ml of the obtained culture can be inoculated into 20 ml of the fermentation medium in a 500-ml flask.
  • the cultivation can be carried out at 37 0 C for 16 h by using a reciprocal shaker at the agitation speed of 115 rpm.
  • the amounts of L-lysine and residual glucose in the medium can be measured by a known method (Biotech-analyzer AS210 manufactured by Sakura Seiki Co.). Then, the yield of L-lysine can be calculated relative to consumed glucose for each of the strains.
  • composition of the fermentation medium (g/1) is as follows:
  • the pH is adjusted to 7.0 by KOH and the medium is autoclaved at 115 0 C for 10 min.
  • Glucose and MgSO 4 -7H 2 O are sterilized separately.
  • CaCO 3 is dry-heat sterilized at 180 0 C for 2 hours and added to the medium for a final concentration of 30 g/1.
  • Example 5 The effect of introduction of the mutant ptsG gene on L-cvsteine production.
  • strain JM15(ydeD) can be transformed with plasmid pMWl 18-ptsG-mut or pMW118-ptsG-wt.
  • E. coli JM15(ydeD) is a derivative of E. coli JM15 (US Patent No. 6,218,168), which can be transformed with DNA having the ydeD gene encoding a membrane protein, and is not involved in a biosynthetic pathway of any L-amino acid (US Patent No. 5,972,663).
  • the strain JMl 5 (CGSC # 5042) can be obtained from The Coli Genetic Stock Collection at the E.coli Genetic Resource Center, MCD Biology Department, Yale University (http://cgsc.biology.yale.edu/).
  • Example 6 The effect of introduction of the mutant ptsG gene on L-leucine production
  • the E. coli L-leucine-producing strain 57 can be transformed with plasmid pMWl 18-ptsG-mut or pMWl 18-ptsG-wt.
  • the strain 57 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) ( Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 st D ⁇ rozhny proezd, 1) on May 19, 1997 under accession number VKPM B-7386.
  • VKPM Russian National Collection of Industrial Microorganisms
  • Both E. coli strains can be cultured for 18-24 hours at 37°C on L-agar plates.
  • the strains can be grown on a rotary shaker (250 rpm) at 32°C for 18 hours in 20x200-mm test tubes containing 2 ml of L-broth supplemented with 4% sucrose.
  • the fermentation medium can be inoculated with 0.21 ml of seed material (10%).
  • the fermentation can be performed in 2 ml of a minimal fermentation medium in 20x200-mm test tubes.
  • Cells can be grown for 48-72 hours at 32°C with shaking at 250 rpm.
  • composition of the fermentation medium (g/1) (pH 7.2) is as follows: Glucose 60.0
  • Glucose and CaCO 3 are sterilized separately.
  • Example 7 The effect of introduction of the mutant ptsG gene on L-histidine production
  • the E. coli L-histidine-producing strain 80 can be transformed with plasmid pMWl 18-ptsG-mut or pMWl 18-ptsG-wt.
  • the strain 80 has been described in Russian patent 2119536 and deposited in the Russian National Collection of Industrial Microorganisms ( Russian, 117545 Moscow, 1st Dorozhny proezd, 1) on October 15, 1999 under accession number VKPM B-7270 and then converted to a deposit under the Budapest Treaty on My 12, 2004. Both E.
  • composition of the fermentation medium (g/1) is as follows (pH 6.0):
  • Glucose, proline, betaine and CaCO 3 are sterilized separately.
  • the pH is adjusted to 6.0 before sterilization.
  • Example 8 The effect of introduction of the mutant ptsG gene on L-glutamate production.
  • the E. coli L-glutamate-producing strain VL334thrC + can be transformed with plasmid pMWl 18- ⁇ tsG-mut or pMWl 18- ⁇ tsG-wt.
  • the strain VL334thrC + has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (USD, 117545 Moscow, 1 st Dorozhny proezd, 1) on December 6, 2004 under the accession number VKPM B-8961 and then converted to a deposit under the Budapest Treaty on December 8, 2004.
  • Both strains VL334thrC7pMWl 18-ptsG-mut and VL334thrC + /pMWl 18-ptsG-wt, can be grown for 18-24 hours at 37 0 C on L-agar plates. Then, one loop of the cells can be transferred into test tubes containing 2ml of fermentation medium.
  • the fermentation medium contains glucose (60g/l), ammonium sulfate (25 g/l) 5 KH 2 PO 4 (2g/l), MgSO 4 (1 g/lj, thiamine (0.1 mg/ml), L-isoleucine (70 ⁇ g/ml), and CaCO 3 (25 g/1).
  • the pH is adjusted to 7.2.
  • Example 9 The effect of introduction of the mutant ptsG gene on L- phenylalanine production.
  • the E. coli L-phenylalanine-producing strain AJ12739 can be transformed with plasmid pMWl 18-ptsG-mut or pMWl 18-ptsG-wt.
  • the strain AJ12739 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (USD, 117545 Moscow, 1 st Dorozhny proezd, 1) on November 6, 2001 under accession no. VKPM B- 8197 and then converted to a deposit under the Budapest Treaty on August 23, 2002.
  • Both strains can be cultivated at 37 0 C for 18 hours in a nutrient broth, and 0.3 ml of the obtained culture can each be inoculated into 3 ml of a fermentation medium in a 20x200-mm test tube and cultivated at 37°C for 48 hours with shaking on a rotary shaker. After cultivation, the amount of phenylalanine which accumulates in the medium can be determined by TLC.
  • the 10xl5-cm TLC plates coated with 0.11 -mm layers of Sorbfil silica gel containing no fluorescent indicator can be used.
  • a solution of ninhydrin (2%) in acetone can be used as a visualizing reagent.
  • composition of the fermentation medium (g/1) is as follows:
  • Glucose and magnesium sulfate are sterilized separately.
  • CaCO 3 is dry-heat sterilized at 180° for 2 hours. The pH is adjusted to 7.0.
  • Example 10 The effect of introduction of the mutant ptsG gene on L-tryptophan production.
  • the E. coli L-tryptophan-producing strain SV 164 can be transformed with plasmid pMWl 18-ptsG-mut or pMWl 18-ptsG-wt.
  • the strain SV164 has the trpE allele encoding anthranilate synthase free from feedback inhibition by tryptophan.
  • the plasmid pGH5 harbors a mutant serA gene encoding phosphoglycerate dehydrogenase free from feedback inhibition by serine.
  • the strain SVl 64 (pGH5) was described in detail in US patent No. 6,180,373 or European patent 0662143.
  • Both strains, SV164(pGH5)/pMW118-ptsG-mut and SV164(pGH5)/pMW118-ptsG- wt can be cultivated with shaking at 32°C for 18 hours in 3 ml of nutrient broth supplemented with tetracycline (10 mg/ml, marker of pGH5 plasmid).
  • the obtained cultures (0.3 ml each) can be inoculated into 3 ml of a fermentation medium containing tetracycline (10 mg/ml) in 20 x 200-mm test tubes, and cultivated at 32 0 C for 72 hours with a rotary shaker at 250 rpm.
  • the amount of tryptophan which accumulates in the medium can be determined by TLC as described in Example 9.
  • the fermentation medium components are listed in Table 4, but should be sterilized in separate groups (A, B, C, D, E, F, and G) 3 as shown, to avoid adverse interactions during sterilization.
  • Table 4
  • Solution A had pH 7.1 adjusted by NH 4 OH.
  • Example 11 The effect of introduction of the mutant ptsG gene on L-proline production.
  • the E. coli L-proline-producing strain 702ilvA can be transformed with plasmid pMWl 18- ⁇ tsG-mut or pMWl 18- ⁇ tsG-wt.
  • the strain 702ilvA has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (USD, 117545 Moscow, 1 st Dorozhny proezd, 1) on July 18, 2000 under accession number VKPM B- 8012 and then converted to a deposit under the Budapest Treaty on May 18, 2001.
  • VKPM Russian National Collection of Industrial Microorganisms
  • Both E. coli strains 702ilvA/pMWl 18-ptsG-mut and 702ilvA/pMWl 18-ptsG-wt, can be grown for 18-24 hours at 37°C on L-agar plates. Then, these strains can be cultivated under the same conditions as in Example 8.
  • Example 12 The effect of introduction of the mutant ytsG gene on L-arginine production.
  • the E. coli L-arginine-producing strain 382 can be transformed with plasmid pMWl 18- ⁇ tsG-mut or pMWl 18- ⁇ tsG-wt.
  • the strain 382 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (USD, 117545 Moscow, 1 st Dorozhny proezd, 1) on April 10, 2000 under accession number VKPM B- 7926 and then converted to a deposit under the Budapest Treaty on May 18, 2001.
  • VKPM Russian National Collection of Industrial Microorganisms
  • Both strains, 382/ ⁇ MWl 18- ⁇ tsG-mut and 382/pMWl 18-ptsG-wt can be cultivated with shaking at 37°C for 18 hours in 3 ml of nutrient broth, and 0.3 ml of the obtained cultures were inoculated into 2 ml of a fermentation medium in 20 x 200-mm test tubes and cultivated at 32 0 C for 48 hours on a rotary shaker.
  • a solution of ninhydrin (2%) in acetone can be used as a visualizing reagent.
  • a spot containing L-arginine can be cut out, L-arginine can be eluted with 0.5% water solution of CdCl 2 , and the amount of L-arginine can be estimated spectrophotometrically at 540 nm.
  • composition of the fermentation medium (g/1) is as follows:
  • Glucose and magnesium sulfate were sterilized separately.
  • CaCO 3 was dry-heat sterilized at 18O 0 C for 2 hours. The pH was adjusted to 7.0.
  • the present invention provides a novel mutant II GI °, L-amino acid-producing bactiera whose amino acid production is enhanced, and a method for producing L-amino acids using these bacteria.
  • the present invention is useful for amino acid production.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de production d'un acide L-aminé, par exemple la L-thréonine, en utilisant une bactérie de la famille des entérobactéries, ladite bactérie ayant été modifiée pour augmenter l'activité d'une PTS perméase mutante spécifique du glucose.
PCT/JP2007/056757 2006-03-23 2007-03-22 Procede de production d'un acide l-amine en utilisant une bacterie de la famille des enterobacteries WO2007119576A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2006109061/13A RU2335536C2 (ru) 2006-03-23 2006-03-23 МУТАНТНАЯ IIB/IIC СУБЪЕДИНИЦА ГЛЮКОЗОСПЕЦИФИЧЕСКОЙ ПЕРМЕАЗЫ СИСТЕМЫ PTS, ФРАГМЕНТ ДНК, БАКТЕРИЯ, ПРИНАДЛЕЖАЩАЯ К РОДУ Escherichia, - ПРОДУЦЕНТ L-ТРЕОНИНА И СПОСОБ ПОЛУЧЕНИЯ L-ТРЕОНИНА
RU2006109061 2006-03-23
US82682006P 2006-09-25 2006-09-25
US60/826,820 2006-09-25

Publications (2)

Publication Number Publication Date
WO2007119576A1 WO2007119576A1 (fr) 2007-10-25
WO2007119576A9 true WO2007119576A9 (fr) 2008-03-27

Family

ID=38198203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/056757 WO2007119576A1 (fr) 2006-03-23 2007-03-22 Procede de production d'un acide l-amine en utilisant une bacterie de la famille des enterobacteries

Country Status (1)

Country Link
WO (1) WO2007119576A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086790A1 (es) * 2011-06-29 2014-01-22 Metabolic Explorer Sa Un microorganismo para la produccion de metionina con importacion de glucosa mejorada
CN104411821B (zh) * 2012-06-18 2017-08-08 代谢探索者公司 用于发酵生产甲硫氨酸的重组微生物
KR20140102393A (ko) 2013-02-13 2014-08-22 씨제이제일제당 (주) L-쓰레오닌 생산능을 가지는 재조합 에스케리키아 속 미생물 및 이를 이용한 l-쓰레오닌의 생산방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10132945A1 (de) * 2001-07-06 2003-01-16 Degussa Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung von Stämmen der Familie Enterobacteriaceae
DE10316109A1 (de) * 2003-04-09 2004-10-21 Degussa Ag Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung von Stämmen der Familie Enterobacteriaceae

Also Published As

Publication number Publication date
WO2007119576A1 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
US7919283B2 (en) Method for producing an L-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of any of the cynT, cynS, cynX or cynR gene or combination thereof
US20090209011A1 (en) Method for Producing an L-Amino Acid Using a Bacterium of the Enterobacteriaceae Family With Enhanced Expression of the fucPIKUR Operon
EP2007873B1 (fr) PROCÉDÉ DE PRODUCTION D'UN ACIDE L-AMINÉ PAR UNE BACTÉRIE DE LA FAMILLE DES ENTEROBACTÉRIACÉE AVEC EXPRESSION ATTENUÉE DE L'AGRÉGAT sfmACDFH-fimZ OU DU GÈNE fimZ
WO2007136133A1 (fr) Procédé de production d'un acide l-aminé en utilisant une bactérie de la famille des entérobactéries
US20130109063A1 (en) Method for Producing an L-Amino Acid Using a Bacterium of the Enterobacteriaceae Family
EP1883704B1 (fr) Methodes de production d'un l-amino-acide en utilisant une bacterie de la famille des enterobacteriacees avec l'expression attenuee du gene kefb
US8691537B2 (en) Method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family with attenuated expression of the rcsA gene
EP2044193A1 (fr) Procédé de production d'un acide l-aminé au moyen d'une bactérie de la famille des enterobacteriaceae avec expression atténuée de l'opéron tspab
EP1856243B1 (fr) Procédé de production d'un l-acide aminé en utilisant d'une bacterie issue de la famille des enterobacteriaceae présentant une expression attenuée du gène leuo
EP1929027A1 (fr) UNE MÉTHODE POUR PRODUIRE UN ACIDE L-AMINÉ AU MOYEN D UNE BACTÉRIE DE LA FAMILLE DES ENTÉROBACTÉRIACEAE À EXPRESSION ATTÉNUÉE DU GÈNE ybiV
WO2008032757A1 (fr) PROCÉDÉ DE FABRICATION D'UN ACIDE L-AMINO À L'AIDE D'UNE BACTÉRIE DE LA FAMILLE DES ENTEROBACTERIACEAE AVEC UNE EXPRESSION AMÉLIORÉE DE L'OPÉRON alsABC
WO2007119891A9 (fr) PROCÉDÉ DE PRODUCTION D'UN ACIDE L-AMINÉ À L'AIDE D'UNE BACTÉRIE DE LA FAMILLE DES ENTEROBACTERIACEAE À EXPRESSION ATTÉNUÉE DU GÈNE fhuA
WO2007119880A1 (fr) Procédé de production d'un acide l-aminé au moyen d'une bactérie appartenant à la famille des enterobacteriaceae qui a été modifiée de façon à supprimer la formation de curli
WO2007119576A9 (fr) Procede de production d'un acide l-amine en utilisant une bacterie de la famille des enterobacteries
EP1976994A1 (fr) Procédé de production d'un acide l-aminé en utilisant une bactérie de la famille des entérobactériacées présentant une expression atténuée du gène aldh
WO2007083789A1 (fr) PROCÉDÉ DE PRODUCTION DE L-AMINOACIDE EN UTILISANT UNE BACTÉRIE DE LA FAMILLE DES ENTÉROBACTÉRIACÉES PRÉSENTANT UNE EXPRESSION ATTÉNUÉE DU GÈNE yfeH
WO2009014259A1 (fr) Procédé permettant de produire un acide aminé l à l'aide d'une bactérie appartenant à la famille des entérobactéries ayant une expression atténuée du gène yncd
WO2008105276A1 (fr) Procédé de fabrication d'un l-amino acide à l'aide d'une bactérie de la famille des enterobacteriaceae avec une expression atténuée de l'opéron ycbponme (opéron ssueadcb)
WO2007083788A1 (fr) Procede de production d’un acide l-amine a l’aide d’une bacterie de la famille des enterobacteriaceae a expression attenuee du gene lrha
EP1856242A2 (fr) Procede de production d'un l-aminoacide au moyen d'une bacterie de la famille enterobacteriaceae presentant une expression du gene nac attenuee
WO2008004682A1 (fr) Procédé de production d'un acide l-aminé au moyen d'une bactérie de la famille des enterobacteriaceae avec expression atténuée de l'agrégat yrah-r
WO2007139220A1 (fr) PROCÉDÉ DE PRODUCTION D'UN L-AMINOACIDE AU MOYEN D'UNE BACTÉRIE DE LA FAMILLE ENTEROBACTERIACEAE PRÉSENTANT UNE EXPRESSION ATTÉNUÉE DU GROUPE yehABCDE
WO2007086547A1 (fr) Procédé de production d'un acide l-amino à l'aide d'une bactérie de la famille des enterobacteriaceae avec une expression atténuée du gène yrbg
WO2007119881A1 (fr) Procédé de production d'un acide l-aminé à l'aide d'une bactérie de la famille des entérobactériacées avec une expression attenuée du gène ybda
WO2009022755A1 (fr) Procédé de production d'acide l-amino au moyen d'une bactérie de la famille enterobacteriaceae avec une expression atténuée du gène chac

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07740195

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07740195

Country of ref document: EP

Kind code of ref document: A1